- Home
- RMCO vs TNXP Comparison
RMCO vs TNXP Comparison
Compare RMCO & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- TNXP
- Stock Information
- Founded
- RMCO 2021
- TNXP 2007
- Country
- RMCO United States
- TNXP United States
- Employees
- RMCO N/A
- TNXP N/A
- Industry
- RMCO Multi-Sector Companies
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- TNXP Health Care
- Exchange
- RMCO Nasdaq
- TNXP Nasdaq
- Market Cap
- RMCO 13.9M
- TNXP 15.1M
- IPO Year
- RMCO N/A
- TNXP N/A
- Fundamental
- Price
- RMCO $1.00
- TNXP $0.15
- Analyst Decision
- RMCO
- TNXP Strong Buy
- Analyst Count
- RMCO 0
- TNXP 2
- Target Price
- RMCO N/A
- TNXP $53.50
- AVG Volume (30 Days)
- RMCO 17.5K
- TNXP 26.1M
- Earning Date
- RMCO 11-18-2024
- TNXP 11-07-2024
- Dividend Yield
- RMCO N/A
- TNXP N/A
- EPS Growth
- RMCO N/A
- TNXP N/A
- EPS
- RMCO N/A
- TNXP N/A
- Revenue
- RMCO $644,293.00
- TNXP $12,458,000.00
- Revenue This Year
- RMCO N/A
- TNXP $62.53
- Revenue Next Year
- RMCO N/A
- TNXP $26.17
- P/E Ratio
- RMCO N/A
- TNXP N/A
- Revenue Growth
- RMCO 126.99
- TNXP N/A
- 52 Week Low
- RMCO $0.70
- TNXP $0.12
- 52 Week High
- RMCO $22.97
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- RMCO 58.33
- TNXP 32.40
- Support Level
- RMCO $0.87
- TNXP $0.14
- Resistance Level
- RMCO $0.99
- TNXP $0.18
- Average True Range (ATR)
- RMCO 0.08
- TNXP 0.02
- MACD
- RMCO 0.00
- TNXP 0.02
- Stochastic Oscillator
- RMCO 100.00
- TNXP 28.11
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.